{"id":32452,"date":"2020-05-19T07:38:30","date_gmt":"2020-05-19T05:38:30","guid":{"rendered":"https:\/\/wordpress-783423-2671269.cloudwaysapps.com\/?p=32452"},"modified":"2025-01-29T14:03:55","modified_gmt":"2025-01-29T13:03:55","slug":"may-19-2020-dermapharm-holding-se-growth-in-the-first-quarter-of-2020-despite-the-corona-pandemic","status":"publish","type":"post","link":"https:\/\/www.cometis.de\/en\/may-19-2020-dermapharm-holding-se-growth-in-the-first-quarter-of-2020-despite-the-corona-pandemic\/","title":{"rendered":"<span id=\"2020\" class=\"Postdate\">May 19, 2020<\/span> | Dermapharm Holding SE: Growth in the first quarter of 2020 despite the corona pandemic"},"content":{"rendered":"<h1>Corporate news<\/h1>\n<p><a class=\"zur\u00fcckbutton\" href=\"https:\/\/cometis.de\/en\/publication-archive-dermapharm\">to the archive<\/a><\/p>\n<p>&nbsp;<\/p>\n<h1><strong><em>Dermapharm Holding SE: Growth in the first quarter of 2020 despite the corona pandemic<\/em><\/strong><\/h1>\n<ul>\n<li>Group revenues increased by 17.7% to EUR 192.5 million<\/li>\n<li>Adjusted Group EBITDA rose by 13.0% to EUR 49.4 million<\/li>\n<li>Corona pandemic leads to increased demand in some therapeutic areas<\/li>\n<li>Management Board confirms forecast for 2020 as a whole<\/li>\n<\/ul>\n<p><strong>Gr\u00fcnwald, 19 May 2020 \u2013 Dermapharm Holding SE (\u201cDermapharm\u201d), a leading manufacturer of patent-free branded pharmaceuticals for selected therapeutic areas in Germany with a growing international presence, published its figures for the first three months of 2020 today. The company increased its revenue by 17.7% to EUR 192.5 million in the reporting period (previous year: EUR 163.6 million). Adjusted earnings before interest, taxes, depreciation and amortisation (EBITDA) also increased by 13.0% to EUR 49.4 million (previous year: EUR 43.7 million). The adjusted EBITDA margin was 25.7%, one percentage point below the previous year\u2019s figure. Unadjusted EBITDA amounted to EUR 49.2 million and the unadjusted EBITDA margin was 25.6%.<\/strong><\/p>\n<p>\u201cWe continued on our growth course in the first three months of fiscal year 2020. The pharmaceutical industry has also been confronted with the corona pandemic and its effects since the beginning of the year. Dermapharm has adapted very quickly to the changed conditions. We immediately took all necessary measures to maintain business operations and at the same time took all necessary precautions to protect our employees,\u201d commented Dr Hans-Georg Feldmeier, CEO of Dermapharm Holding SE.<\/p>\n<p>All production sites of the Dermapharm Group in Germany have been classified as companies with critical infrastructure for the state community in accordance with \u00a7 6 of the BSI-KritisV and maintain operations accordingly even in times of crisis. With a view to the current situation, Feldmeier added: \u201cOn the one hand, our commitment to Germany as a business location pays off here. On the other hand, thanks to the great commitment of our employees, we were able to avoid delivery bottlenecks even in these challenging times.\u201d Increased demand in some therapeutic areas contributed to higher growth in revenue than planned in the first quarter. Inventory effects within the supply chain played a significant role here. Dermapharm expects this demand effect to smooth out again in the further course of the year. Demand declined in the \u201cHerbal Extracts\u201d segment in the wake of the corona pandemic.<\/p>\n<p>Dermapharm significantly increased its revenues in the \u201cBranded pharmaceuticals and other healthcare products\u201d segment in the first quarter of 2020 by 25.8% to EUR 106.2 million (previous year: EUR 84.4 million). The segment\u2019s adjusted EBITDA thus increased by 17.2% to EUR 43.7 million (previous year: EUR 37.3 million). This increase was largely based on increased demand for products used to strengthen the immune system, particularly in the \u201cvitamins\/minerals\/enzymes\u201d therapeutic area, due to the corona pandemic. There was also increased demand for \u201csystemic corticoids,\u201d which have an anti-inflammatory effect and support the weakening of the immune response.<\/p>\n<p>In the \u201cParallel import business\u201d segment, revenues increased by 15.4% to EUR 67.5 million in the reporting period (previous year: EUR 58.5 million). This increase was mainly the result of a rise in demand for re-imported original preparations, which Dermapharm was able to meet by means of intact delivery capability and foresighted stockpiling. Due to the proportional growth of the high-margin product group \u201creimported narcotics\u201d and the increased distribution of \u201cwell-known OTC products\u201d via the company\u2019s own call center, EBITDA in this segment increased disproportionately by 42.9% to EUR 3.0 million (previous year: EUR 2.1 million). The EBITDA margin rose from 3.6% in the first three months of the current fiscal year to 4.4%.<\/p>\n<p>In the \u201cHerbal extracts\u201d segment, Dermapharm generated a revenue contribution of EUR 18.9 million in the first quarter of 2020 (Q1 2019: EUR 20.6 million). The segment recorded weaker demand, especially in Spain and the USA, due to the effects of the corona pandemic. The EBITDA contribution, taking into account the negative result of the FYTA Group\u2019s at-equity investment of EUR -0.9 million, amounted to EUR 3.9 million. This equates to an EBITDA margin of 20.6%.<\/p>\n<p>In view of the business development in the first quarter, Dermapharm confirms its forecast for 2020. The Management Board continues to expect organic growth in Group revenues and EBITDA in the upper single-digit percentage range in each case.<\/p>\n<p>The complete quarterly report is available on the website ir.dermapharm.com as of today.<\/p>\n<p>&nbsp;<\/p>\n<p><strong>Key financial figures for Q1 2020 year-on-year<\/strong><\/p>\n<table width=\"100%\">\n<tbody>\n<tr>\n<td width=\"46%\"><strong>in EUR millions<\/strong><\/td>\n<td width=\"17%\"><strong>Q1 2020<\/strong><\/td>\n<td width=\"17%\"><strong>Q1 2019<\/strong><\/td>\n<td width=\"17%\"><strong>Change<\/strong><\/td>\n<\/tr>\n<tr>\n<td width=\"46%\"><strong>\u00a0<\/strong><\/td>\n<td width=\"17%\"><strong>\u00a0<\/strong><\/td>\n<td width=\"17%\"><strong>\u00a0<\/strong><\/td>\n<td width=\"17%\"><strong>\u00a0<\/strong><\/td>\n<\/tr>\n<tr>\n<td width=\"46%\"><strong>Group revenues<\/strong><\/td>\n<td width=\"17%\"><strong>192.5<\/strong><\/td>\n<td width=\"17%\"><strong>163.6<\/strong><\/td>\n<td width=\"17%\"><strong>+17.7%<\/strong><\/td>\n<\/tr>\n<tr>\n<td width=\"46%\"><em>Branded pharmaceuticals and other healthcare products<\/em><\/td>\n<td width=\"17%\"><em>106.2<\/em><\/td>\n<td width=\"17%\"><em>84.4<\/em><\/td>\n<td width=\"17%\"><em>\u00a0<\/em><\/p>\n<p><em>+25.8%<\/em><\/td>\n<\/tr>\n<tr>\n<td width=\"46%\"><em>Parallel import business<\/em><\/td>\n<td width=\"17%\"><em>67.5<\/em><\/td>\n<td width=\"17%\"><em>58.5<\/em><\/td>\n<td width=\"17%\"><em>+15.4%<\/em><\/td>\n<\/tr>\n<tr>\n<td width=\"46%\"><em>Herbal extracts<\/em><\/td>\n<td width=\"17%\"><em>18.9<\/em><\/td>\n<td width=\"17%\"><em>20.6<\/em><\/td>\n<td width=\"17%\"><em>-8.3%<\/em><\/td>\n<\/tr>\n<tr>\n<td width=\"46%\"><strong>\u00a0<\/strong><\/td>\n<td width=\"17%\"><strong>\u00a0<\/strong><\/td>\n<td width=\"17%\"><strong>\u00a0<\/strong><\/td>\n<td width=\"17%\"><strong>\u00a0<\/strong><\/td>\n<\/tr>\n<tr>\n<td width=\"46%\"><strong>Adjusted* Group EBITDA<\/strong><\/td>\n<td width=\"17%\"><strong>49.4<\/strong><\/td>\n<td width=\"17%\"><strong>43.7<\/strong><\/td>\n<td width=\"17%\"><strong>+13.0%<\/strong><\/td>\n<\/tr>\n<tr>\n<td width=\"46%\"><em>Branded pharmaceuticals and other healthcare products<\/em><\/td>\n<td width=\"17%\"><em>43.7<\/em><\/td>\n<td width=\"17%\"><em>37.3<\/em><\/td>\n<td width=\"17%\"><em>\u00a0<\/em><\/p>\n<p><em>+17.2%<\/em><\/td>\n<\/tr>\n<tr>\n<td width=\"46%\"><em>Parallel import business<\/em><\/td>\n<td width=\"17%\"><em>3.0<\/em><\/td>\n<td width=\"17%\"><em>2.1<\/em><\/td>\n<td width=\"17%\"><em>+42.9%<\/em><\/td>\n<\/tr>\n<tr>\n<td width=\"46%\"><em>Herbal extracts<\/em><\/td>\n<td width=\"17%\"><em>3.9<\/em><\/td>\n<td width=\"17%\">4.5<\/td>\n<td width=\"17%\"><em>-13.3%<\/em><\/td>\n<\/tr>\n<tr>\n<td width=\"46%\"><strong>Adjusted* EBITDA margin (in %)<\/strong><\/td>\n<td width=\"17%\"><strong>25.7<\/strong><\/td>\n<td width=\"17%\"><strong>26.7<\/strong><\/td>\n<td width=\"17%\"><strong>+1.0pp<\/strong><\/td>\n<\/tr>\n<tr>\n<td width=\"46%\"><em>Branded pharmaceuticals and other healthcare products<\/em><\/td>\n<td width=\"17%\"><em>41.1<\/em><\/td>\n<td width=\"17%\"><em>44.2<\/em><\/td>\n<td width=\"17%\"><em>\u00a0<\/em><\/p>\n<p><em>-3.1pp<\/em><\/td>\n<\/tr>\n<tr>\n<td width=\"46%\"><em>Parallel import business<\/em><\/td>\n<td width=\"17%\"><em>4.4<\/em><\/td>\n<td width=\"17%\">3.6<\/td>\n<td width=\"17%\"><em>+0.8pp<\/em><\/td>\n<\/tr>\n<tr>\n<td width=\"46%\"><em>Herbal extracts<\/em><\/td>\n<td width=\"17%\"><em>20.6<\/em><\/td>\n<td width=\"17%\"><em>21.8<\/em><\/td>\n<td width=\"17%\"><em>-1.2pp<\/em><\/td>\n<\/tr>\n<tr>\n<td width=\"46%\"><strong>\u00a0<\/strong><\/td>\n<td width=\"17%\"><strong>\u00a0<\/strong><\/td>\n<td width=\"17%\"><strong>\u00a0<\/strong><\/td>\n<td width=\"17%\"><strong>\u00a0<\/strong><\/td>\n<\/tr>\n<tr>\n<td width=\"46%\"><strong>Group EBITDA<\/strong><\/td>\n<td width=\"17%\"><strong>49.2<\/strong><\/td>\n<td width=\"17%\"><strong>40.7<\/strong><\/td>\n<td width=\"17%\"><strong>+20.9%<\/strong><\/td>\n<\/tr>\n<tr>\n<td width=\"46%\"><strong>EBITDA margin (in %)<\/strong><\/td>\n<td width=\"17%\"><strong>25.6<\/strong><\/td>\n<td width=\"17%\"><strong>24.9<\/strong><\/td>\n<td width=\"17%\"><strong>+0.7pp<\/strong><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>* Q1 2020 EBITDA adjusted for non-recurring expenses in connection with the acquisition of Allergopharma amounting to EUR 0.2 million.<br \/>\nQ1 2019 EBITDA adjusted by non-recurring expenses of EUR 2.9 million in connection with the acquisition of Euromed and by non-recurring expenses of EUR 0.1 million for consultancy services in connection with further acquisition efforts.<\/p>\n<p><strong>Company profile: <\/strong><\/p>\n<p><strong>Dermapharm \u2013 Pharmaceutical Excellence &#8220;Made in Germany&#8221;<\/strong><\/p>\n<p>Dermapharm is a leading manufacturer of patent-free branded pharmaceuticals for selected markets in Germany. Founded in 1991, the company is based in Gr\u00fcnwald near Munich and has its main manufacturing facility in Brehna near Leipzig. The company&#8217;s integrated business model comprises in-house development, in-house production and distribution of pharmaceuticals and other healthcare products for specifically targeted markets by a trained medical and pharmaceutical sales force. Dermapharm has more than 250 active pharmaceutical ingredients for more than 900 marketing authorizations (Arzneimittelzulassungen), which are marketed as pharmaceuticals, dietary supplements or supplemental balanced diets. This range makes the company unique. Besides Germany, the company&#8217;s core markets also include Austria and Switzerland. The company plans to further expand its international presence. Dermapharm&#8217;s business model also includes a parallel import business that operates under the &#8220;axicorp&#8221; brand. Based on revenues, Dermapharm was among the top five parallel import companies in Germany in 2019. In the &#8220;Herbal extracts&#8221; segment, Dermapharm has access to the growth market for herbal pharmaceuticals through the Spanish company Euromed S.A., one of the leading manufacturers of herbal extracts and natural active ingredients.<\/p>\n<p>With a consistent R&amp;D strategy and numerous successful product and company acquisitions over the past 25 years, Dermapharm has continuously optimized its business and provided external growth impulses in addition to organic growth. Dermapharm intends to continue on this profitable growth course in the future. The company is focusing on a three-pillar strategy: in-house development of new products, increase of its international footprint and further acquisitions.<\/p>\n<p><strong>Contacts<\/strong><\/p>\n<table>\n<tbody>\n<tr>\n<td width=\"307\">Investor Relations &amp; Corporate Communications<br \/>\nBritta Hamberger<br \/>\nPhone: +49 (0)89 \u2013 64186-233<br \/>\nFax: +49 (0)89 \u2013 64186-165E-mail: <a href=\"mailto:ir@dermapharm.com\">ir@dermapharm.com<\/a><\/td>\n<td width=\"307\">cometis AG<br \/>\nClaudius Krause<br \/>\nPhone: +49 (0)611 \u2013 205855-28<br \/>\nFax: +49 (0)611 \u2013 205855-66<br \/>\nE-mail: <a href=\"mailto:ir@dermapharm.com\">ir@dermapharm.com<\/a><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<div class=\"leseprobe-archiv\"><a title=\"Post as PDF\" href=\"https:\/\/cometis.de\/wp-content\/uploads\/2020\/05\/20200519_CN_Dermapharm_Q1_2020_Figures.pdf\" rel=\"noopener noreferrer\">Post as PDF<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Corporate news to the archive &nbsp; Dermapharm Holding SE: Growth in the first quarter of 2020 despite the corona pandemic Group revenues increased by 17.7% to EUR 192.5 million Adjusted Group EBITDA rose by 13.0% to EUR 49.4 million Corona pandemic leads to increased demand in some therapeutic areas Management Board confirms forecast for 2020 [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":98872,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[215,90,212],"tags":[276],"class_list":["post-32452","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-dermapharm-corporate-news-en","category-news-en","category-uncategorized","tag-2020-2"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v26.2 (Yoast SEO v27.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>May 19, 2020 | Dermapharm Holding SE: Growth in the first quarter of 2020 despite the corona pandemic - cometis AG<\/title>\n<meta name=\"description\" content=\"Dermapharm Holding SE, a leading manufacturer of patent-free branded pharmaceuticals for selected therapeutic areas in Germany with a growing international presence, published its figures for the first three months of 2020 today.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.cometis.de\/en\/may-19-2020-dermapharm-holding-se-growth-in-the-first-quarter-of-2020-despite-the-corona-pandemic\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"May 19, 2020 | Dermapharm Holding SE: Growth in the first quarter of 2020 despite the corona pandemic\" \/>\n<meta property=\"og:description\" content=\"Dermapharm Holding SE, a leading manufacturer of patent-free branded pharmaceuticals for selected therapeutic areas in Germany with a growing international presence, published its figures for the first three months of 2020 today.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.cometis.de\/en\/may-19-2020-dermapharm-holding-se-growth-in-the-first-quarter-of-2020-despite-the-corona-pandemic\/\" \/>\n<meta property=\"og:site_name\" content=\"cometis AG\" \/>\n<meta property=\"article:published_time\" content=\"2020-05-19T05:38:30+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-01-29T13:03:55+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.cometis.de\/wp-content\/uploads\/2024\/12-old\/Cometis-Mobile-Logo-1.png\" \/>\n\t<meta property=\"og:image:width\" content=\"171\" \/>\n\t<meta property=\"og:image:height\" content=\"31\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Assistenz cometis AG\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Assistenz cometis AG\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.cometis.de\\\/en\\\/may-19-2020-dermapharm-holding-se-growth-in-the-first-quarter-of-2020-despite-the-corona-pandemic\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.cometis.de\\\/en\\\/may-19-2020-dermapharm-holding-se-growth-in-the-first-quarter-of-2020-despite-the-corona-pandemic\\\/\"},\"author\":{\"name\":\"Assistenz cometis AG\",\"@id\":\"https:\\\/\\\/www.cometis.de\\\/en\\\/#\\\/schema\\\/person\\\/5359bae3178840cd846706150aa69cd1\"},\"headline\":\"May 19, 2020 | Dermapharm Holding SE: Growth in the first quarter of 2020 despite the corona pandemic\",\"datePublished\":\"2020-05-19T05:38:30+00:00\",\"dateModified\":\"2025-01-29T13:03:55+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.cometis.de\\\/en\\\/may-19-2020-dermapharm-holding-se-growth-in-the-first-quarter-of-2020-despite-the-corona-pandemic\\\/\"},\"wordCount\":1109,\"publisher\":{\"@id\":\"https:\\\/\\\/www.cometis.de\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/www.cometis.de\\\/en\\\/may-19-2020-dermapharm-holding-se-growth-in-the-first-quarter-of-2020-despite-the-corona-pandemic\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.cometis.de\\\/wp-content\\\/uploads\\\/2022\\\/06\\\/icon_newsroom.svg\",\"keywords\":[\"2020\"],\"articleSection\":[\"Dermapharm Corporate News\",\"News\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.cometis.de\\\/en\\\/may-19-2020-dermapharm-holding-se-growth-in-the-first-quarter-of-2020-despite-the-corona-pandemic\\\/\",\"url\":\"https:\\\/\\\/www.cometis.de\\\/en\\\/may-19-2020-dermapharm-holding-se-growth-in-the-first-quarter-of-2020-despite-the-corona-pandemic\\\/\",\"name\":\"May 19, 2020 | Dermapharm Holding SE: Growth in the first quarter of 2020 despite the corona pandemic - cometis AG\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.cometis.de\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.cometis.de\\\/en\\\/may-19-2020-dermapharm-holding-se-growth-in-the-first-quarter-of-2020-despite-the-corona-pandemic\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.cometis.de\\\/en\\\/may-19-2020-dermapharm-holding-se-growth-in-the-first-quarter-of-2020-despite-the-corona-pandemic\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.cometis.de\\\/wp-content\\\/uploads\\\/2022\\\/06\\\/icon_newsroom.svg\",\"datePublished\":\"2020-05-19T05:38:30+00:00\",\"dateModified\":\"2025-01-29T13:03:55+00:00\",\"description\":\"Dermapharm Holding SE, a leading manufacturer of patent-free branded pharmaceuticals for selected therapeutic areas in Germany with a growing international presence, published its figures for the first three months of 2020 today.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.cometis.de\\\/en\\\/may-19-2020-dermapharm-holding-se-growth-in-the-first-quarter-of-2020-despite-the-corona-pandemic\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.cometis.de\\\/en\\\/may-19-2020-dermapharm-holding-se-growth-in-the-first-quarter-of-2020-despite-the-corona-pandemic\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.cometis.de\\\/en\\\/may-19-2020-dermapharm-holding-se-growth-in-the-first-quarter-of-2020-despite-the-corona-pandemic\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.cometis.de\\\/wp-content\\\/uploads\\\/2022\\\/06\\\/icon_newsroom.svg\",\"contentUrl\":\"https:\\\/\\\/www.cometis.de\\\/wp-content\\\/uploads\\\/2022\\\/06\\\/icon_newsroom.svg\",\"width\":172,\"height\":172},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.cometis.de\\\/en\\\/may-19-2020-dermapharm-holding-se-growth-in-the-first-quarter-of-2020-despite-the-corona-pandemic\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.cometis.de\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Uncategorized\",\"item\":\"https:\\\/\\\/www.cometis.de\\\/en\\\/category\\\/uncategorized\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"May 19, 2020 | Dermapharm Holding SE: Growth in the first quarter of 2020 despite the corona pandemic\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.cometis.de\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/www.cometis.de\\\/en\\\/\",\"name\":\"cometis AG\",\"description\":\"Deutschlands f\u00fchrende Investor Relations Agentur\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.cometis.de\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.cometis.de\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.cometis.de\\\/en\\\/#organization\",\"name\":\"cometis AG\",\"alternateName\":\"Deutschlands f\u00fchrende Investor Relations Agentur\",\"url\":\"https:\\\/\\\/www.cometis.de\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.cometis.de\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.cometis.de\\\/wp-content\\\/uploads\\\/2024\\\/12-old\\\/Cometis-Mobile-Logo-1.png\",\"contentUrl\":\"https:\\\/\\\/www.cometis.de\\\/wp-content\\\/uploads\\\/2024\\\/12-old\\\/Cometis-Mobile-Logo-1.png\",\"width\":171,\"height\":31,\"caption\":\"cometis AG\"},\"image\":{\"@id\":\"https:\\\/\\\/www.cometis.de\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.linkedin.com\\\/company\\\/cometis-ag\\\/\",\"https:\\\/\\\/www.youtube.com\\\/user\\\/cometisAG\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.cometis.de\\\/en\\\/#\\\/schema\\\/person\\\/5359bae3178840cd846706150aa69cd1\",\"name\":\"Assistenz cometis AG\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/43da04bfaca4f56c43243bf29c1e464e0dbbc04dfd398bead7b5594ba02bcec9?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/43da04bfaca4f56c43243bf29c1e464e0dbbc04dfd398bead7b5594ba02bcec9?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/43da04bfaca4f56c43243bf29c1e464e0dbbc04dfd398bead7b5594ba02bcec9?s=96&d=mm&r=g\",\"caption\":\"Assistenz cometis AG\"},\"url\":\"https:\\\/\\\/www.cometis.de\\\/en\\\/author\\\/assistenz-cometis-ag\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"May 19, 2020 | Dermapharm Holding SE: Growth in the first quarter of 2020 despite the corona pandemic - cometis AG","description":"Dermapharm Holding SE, a leading manufacturer of patent-free branded pharmaceuticals for selected therapeutic areas in Germany with a growing international presence, published its figures for the first three months of 2020 today.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.cometis.de\/en\/may-19-2020-dermapharm-holding-se-growth-in-the-first-quarter-of-2020-despite-the-corona-pandemic\/","og_locale":"en_US","og_type":"article","og_title":"May 19, 2020 | Dermapharm Holding SE: Growth in the first quarter of 2020 despite the corona pandemic","og_description":"Dermapharm Holding SE, a leading manufacturer of patent-free branded pharmaceuticals for selected therapeutic areas in Germany with a growing international presence, published its figures for the first three months of 2020 today.","og_url":"https:\/\/www.cometis.de\/en\/may-19-2020-dermapharm-holding-se-growth-in-the-first-quarter-of-2020-despite-the-corona-pandemic\/","og_site_name":"cometis AG","article_published_time":"2020-05-19T05:38:30+00:00","article_modified_time":"2025-01-29T13:03:55+00:00","og_image":[{"width":171,"height":31,"url":"https:\/\/www.cometis.de\/wp-content\/uploads\/2024\/12-old\/Cometis-Mobile-Logo-1.png","type":"image\/png"}],"author":"Assistenz cometis AG","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Assistenz cometis AG","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.cometis.de\/en\/may-19-2020-dermapharm-holding-se-growth-in-the-first-quarter-of-2020-despite-the-corona-pandemic\/#article","isPartOf":{"@id":"https:\/\/www.cometis.de\/en\/may-19-2020-dermapharm-holding-se-growth-in-the-first-quarter-of-2020-despite-the-corona-pandemic\/"},"author":{"name":"Assistenz cometis AG","@id":"https:\/\/www.cometis.de\/en\/#\/schema\/person\/5359bae3178840cd846706150aa69cd1"},"headline":"May 19, 2020 | Dermapharm Holding SE: Growth in the first quarter of 2020 despite the corona pandemic","datePublished":"2020-05-19T05:38:30+00:00","dateModified":"2025-01-29T13:03:55+00:00","mainEntityOfPage":{"@id":"https:\/\/www.cometis.de\/en\/may-19-2020-dermapharm-holding-se-growth-in-the-first-quarter-of-2020-despite-the-corona-pandemic\/"},"wordCount":1109,"publisher":{"@id":"https:\/\/www.cometis.de\/en\/#organization"},"image":{"@id":"https:\/\/www.cometis.de\/en\/may-19-2020-dermapharm-holding-se-growth-in-the-first-quarter-of-2020-despite-the-corona-pandemic\/#primaryimage"},"thumbnailUrl":"https:\/\/www.cometis.de\/wp-content\/uploads\/2022\/06\/icon_newsroom.svg","keywords":["2020"],"articleSection":["Dermapharm Corporate News","News"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.cometis.de\/en\/may-19-2020-dermapharm-holding-se-growth-in-the-first-quarter-of-2020-despite-the-corona-pandemic\/","url":"https:\/\/www.cometis.de\/en\/may-19-2020-dermapharm-holding-se-growth-in-the-first-quarter-of-2020-despite-the-corona-pandemic\/","name":"May 19, 2020 | Dermapharm Holding SE: Growth in the first quarter of 2020 despite the corona pandemic - cometis AG","isPartOf":{"@id":"https:\/\/www.cometis.de\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.cometis.de\/en\/may-19-2020-dermapharm-holding-se-growth-in-the-first-quarter-of-2020-despite-the-corona-pandemic\/#primaryimage"},"image":{"@id":"https:\/\/www.cometis.de\/en\/may-19-2020-dermapharm-holding-se-growth-in-the-first-quarter-of-2020-despite-the-corona-pandemic\/#primaryimage"},"thumbnailUrl":"https:\/\/www.cometis.de\/wp-content\/uploads\/2022\/06\/icon_newsroom.svg","datePublished":"2020-05-19T05:38:30+00:00","dateModified":"2025-01-29T13:03:55+00:00","description":"Dermapharm Holding SE, a leading manufacturer of patent-free branded pharmaceuticals for selected therapeutic areas in Germany with a growing international presence, published its figures for the first three months of 2020 today.","breadcrumb":{"@id":"https:\/\/www.cometis.de\/en\/may-19-2020-dermapharm-holding-se-growth-in-the-first-quarter-of-2020-despite-the-corona-pandemic\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.cometis.de\/en\/may-19-2020-dermapharm-holding-se-growth-in-the-first-quarter-of-2020-despite-the-corona-pandemic\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.cometis.de\/en\/may-19-2020-dermapharm-holding-se-growth-in-the-first-quarter-of-2020-despite-the-corona-pandemic\/#primaryimage","url":"https:\/\/www.cometis.de\/wp-content\/uploads\/2022\/06\/icon_newsroom.svg","contentUrl":"https:\/\/www.cometis.de\/wp-content\/uploads\/2022\/06\/icon_newsroom.svg","width":172,"height":172},{"@type":"BreadcrumbList","@id":"https:\/\/www.cometis.de\/en\/may-19-2020-dermapharm-holding-se-growth-in-the-first-quarter-of-2020-despite-the-corona-pandemic\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.cometis.de\/en\/"},{"@type":"ListItem","position":2,"name":"Uncategorized","item":"https:\/\/www.cometis.de\/en\/category\/uncategorized\/"},{"@type":"ListItem","position":3,"name":"May 19, 2020 | Dermapharm Holding SE: Growth in the first quarter of 2020 despite the corona pandemic"}]},{"@type":"WebSite","@id":"https:\/\/www.cometis.de\/en\/#website","url":"https:\/\/www.cometis.de\/en\/","name":"cometis AG","description":"Deutschlands f\u00fchrende Investor Relations Agentur","publisher":{"@id":"https:\/\/www.cometis.de\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.cometis.de\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.cometis.de\/en\/#organization","name":"cometis AG","alternateName":"Deutschlands f\u00fchrende Investor Relations Agentur","url":"https:\/\/www.cometis.de\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.cometis.de\/en\/#\/schema\/logo\/image\/","url":"https:\/\/www.cometis.de\/wp-content\/uploads\/2024\/12-old\/Cometis-Mobile-Logo-1.png","contentUrl":"https:\/\/www.cometis.de\/wp-content\/uploads\/2024\/12-old\/Cometis-Mobile-Logo-1.png","width":171,"height":31,"caption":"cometis AG"},"image":{"@id":"https:\/\/www.cometis.de\/en\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.linkedin.com\/company\/cometis-ag\/","https:\/\/www.youtube.com\/user\/cometisAG"]},{"@type":"Person","@id":"https:\/\/www.cometis.de\/en\/#\/schema\/person\/5359bae3178840cd846706150aa69cd1","name":"Assistenz cometis AG","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/43da04bfaca4f56c43243bf29c1e464e0dbbc04dfd398bead7b5594ba02bcec9?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/43da04bfaca4f56c43243bf29c1e464e0dbbc04dfd398bead7b5594ba02bcec9?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/43da04bfaca4f56c43243bf29c1e464e0dbbc04dfd398bead7b5594ba02bcec9?s=96&d=mm&r=g","caption":"Assistenz cometis AG"},"url":"https:\/\/www.cometis.de\/en\/author\/assistenz-cometis-ag\/"}]}},"_links":{"self":[{"href":"https:\/\/www.cometis.de\/en\/wp-json\/wp\/v2\/posts\/32452","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.cometis.de\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.cometis.de\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.cometis.de\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.cometis.de\/en\/wp-json\/wp\/v2\/comments?post=32452"}],"version-history":[{"count":0,"href":"https:\/\/www.cometis.de\/en\/wp-json\/wp\/v2\/posts\/32452\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.cometis.de\/en\/wp-json\/wp\/v2\/media\/98872"}],"wp:attachment":[{"href":"https:\/\/www.cometis.de\/en\/wp-json\/wp\/v2\/media?parent=32452"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.cometis.de\/en\/wp-json\/wp\/v2\/categories?post=32452"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.cometis.de\/en\/wp-json\/wp\/v2\/tags?post=32452"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}